Dive Brief:
- Johnson & Johnson is opening the Asia Pacific Innovation Center to foster drug discovery and development in the region, while addressing unmet medical needs of populations in the Asia Pacific region.
- The Innovation Center will have a presence not only in China, but also Singapore, Australia, and Japan. The goal is to bring together local science and technology experts to create promising early-stage opportunities that can then be further developed.
- Several collaborative projects have already started to yield interesting early-stage results.
Dive Insight:
J&J has had a presence in China for the last 30 years, which has made the establishment of the Asia Pacific Innovation Center that much easier. So far, there have been notable breakthroughs as a result of collaborative work at the center, including early-stage discoveries that have therapeutic potential for inflammatory bowel disease and pain relief.
The Center also has numerous ongoing projects designed to develop antibody-based treatments for cancer, and other therapeutic breakthroughs.